Skip to main content
All lobbying filings

EDWARDS LIFESCIENCES, LLC

Lobbying for EDWARDS LIFESCIENCES LLC

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $350,000.00 expenses · posted Jan 20, 2026

Official filing document

 Bills named in this filing 2
  • HR 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
 Lobbying activity 3
Health Issues

Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials

Medicare/Medicaid

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

Trade (domestic/foreign)

Japan Reimbursement of Medical Devices

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem